Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis

被引：1
|
作者：
Sandborn, William J.
Van Assche, Gert A.
Reinisch, Walter
Colombel, Jean-Frederic
D'Haens, Geert R.
Wolf, Douglas C.
Kron, Martina
Tighe, Mary Beth
Lazar, Andreas
Thakkar, Roopal
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S123 / S124
页数：2
相关论文
共 50 条
  • [41] First Oral Drug for Moderate-To-Severe Ulcerative Colitis
    Aschenbrenner, Diane S.
    [J]. AMERICAN JOURNAL OF NURSING, 2018, 118 (09) : 22 - 22
  • [42] Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis
    Miyoshi, Jun
    Matsuura, Minoru
    Hisamatsu, Tadakazu
    [J]. EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 1 - 8
  • [43] A Case of Successful Remission in Moderate-to-Severe Steroid Refractory Ulcerative Colitis Using Herbal Therapy
    Lee, Alice
    Mandaliya, Rohan
    Mattar, Mark
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1103 - S1104
  • [44] VARSITY: Vedolizumab showed superior Efficacy than that of Adalimumab in terms of clinical Remission and Mucosal Healing in Patients with moderate to severe active Ulcerative colitis
    不详
    [J]. VISCERAL MEDICINE, 2019, 35 (05) : 330 - 330
  • [45] Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
    Taxonera, C.
    Estelles, J.
    Fernandez-Blanco, I.
    Merino, O.
    Marin-Jimenez, I.
    Barreiro-de Acosta, M.
    Saro, C.
    Garcia-Sanchez, V.
    Gento, E.
    Bastida, G.
    Gisbert, J. P.
    Vera, I.
    Martinez-Montiel, P.
    Garcia-Moran, S.
    Sanchez, M. C.
    Mendoza, J. L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (03) : 340 - 348
  • [46] Induction of remission in moderate-to-severe steroid refractory ulcerative colitis using patient-driven non-pharmacologic therapy
    Lee, Alice M.
    Mandaliya, Rohan
    Mattar, Mark C.
    [J]. ADVANCES IN INTEGRATIVE MEDICINE, 2018, 5 (03) : 119 - 121
  • [47] Cost Per Clinical Remission and Clinical Response of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis
    Mallow, Peter
    Rizzo, John
    Queener, MaryKay
    Gathany, Timothy
    Lofland, Jennifer
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S515 - S516
  • [48] Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis
    Yang, Zheng
    Ye, Xiao-Qing
    Zhu, Yu-Zhen
    Liu, Zhou
    Zou, Ying
    Deng, Ying
    Guo, Can-Can
    Garg, Sushil Kumar
    Feng, Jin-Shan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 86 - 93
  • [49] Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis
    Magro, Fernando
    Estevinho, Maria Manuela
    Dias, Claudia Camila
    Correia, Luis
    Lago, Paula
    Ministro, Paula
    Portela, Francisco
    Feakins, Roger
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 (04): : 551 - 566
  • [50] How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?
    Ghosh, Subrata
    [J]. NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (10): : 540 - 541
12345